Low dose of aspirin, some times referred to as ‘baby aspirin”, is offered to women who considered to be at risk to develop certain complications in pregnancy.

Use of low dose aspirin in high-risk pregnancies has shown significant reduction in occurrence of early onset of pre-eclampsia, a pregnancy related blood pressure condition that is very dangerous for both mother and a baby. However, we know that aspirin is not always effective: at times because some women are resistant to it, or because they don’t take it as prescribed.

On our project ASPIRE we have found that 60 % of women, who were ‘resistant’ to low-dose aspirin by the result of their blood test, were not taking their aspirin as prescribed.

Non-adherence to aspirin is a key for non-response

Therefor our team has set a programme of research that aims to make a better use of aspirin in pregnancy in order to improve health outcome for mothers and their babies.